Journal Article

TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer

Wu, Zhipeng, Xiong, Jianping, Huang, Chunye, Li, Li, Feng, Miao, Deng, Jun, Lei, Wan, Dai, Xiaofeng, Ruan, Ruiwen, Yao, Yangyang, Tang, Xiaomei, Chen, Jingyi

2024

Overview

Background The effectiveness of anti-programmed cell death protein 1(PD-1)/programmed cell death 1 ligand 1(PD-L1) therapy in treating certain types of cancer is associated with the level of PD-L1. However, this relationship has not been observed in colorectal cancer (CRC), and the underlying regulatory mechanism of PD-L1 in CRC remains unclear. Methods Binding of TMEM160 to PD-L1 was determined by co-immunoprecipitation (Co-IP) and GST pull-down assay.The ubiquitination levels of PD-L1 were verified using the ubiquitination assay. Phenotypic experiments were conducted to assess the role of TMEM160 in CRC cells. Animal models were employed to investigate how TMEM160 contributes to tumor growth.The expression and clinical significance of TMEM160 and PD-L1 in CRC tissues were evaluated by immunohistochemistry(IHC). Results In our study, we made a discovery that TMEM160 interacts with PD-L1 and plays a role in stabilizing its expression within a CRC model. Furthermore, we demonstrated that TMEM160 hinders the ubiquitination-dependent degradation of PD-L1 by competing with SPOP for binding to PD-L1 in CRC cells. Regarding functionality, the absence of TMEM160 significantly inhibited the proliferation, invasion, metastasis, clonogenicity, and radioresistance of CRC cells, while simultaneously enhancing the cytotoxic effect of CD8 + T cells on tumor cells. Conversely, the upregulation of TMEM160 substantially increased these capabilities. In severely immunodeficient mice, tumor growth derived from lentiviral vector shTMEM160 cells was lower compared with that derived from shNC control cells. Furthermore, the downregulation of TMEM160 significantly restricted tumor growth in immune-competent BALB/c mice. In clinical samples from patients with CRC, we observed a strong positive correlation between TMEM160 expression and PD-L1 expression, as well as a negative correlation with CD8A expression. Importantly, patients with high TMEM160 expression exhibited a worse prognosis compared with those with low or no TMEM160 expression. Conclusions Our study reveals that TMEM160 inhibits the ubiquitination-dependent degradation of PD-L1 that is mediated by SPOP, thereby stabilizing PD-L1 expression to foster the malignant progress, radioresistance, and immune evasion of CRC cells. These findings suggest that TMEM160 holds potential as a target for the treatment of patients with CRC.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Animal models / Animals / Antibodies / Apoptosis / B7-H1 Antigen - metabolism / Biomedical and Life Sciences / Cancer / Care and treatment / CD8 antigen / CD8-Positive T-Lymphocytes / Cell Biology / Cell culture / Cell death / Cell growth / Cell proliferation / Colorectal cancer / Colorectal Neoplasms - pathology / Complications and side effects / Cytokines and Growth Factors / Cytotoxicity / Health aspects / Humans / Immune evasion / Immune response / Immunodeficiency / Immunohistochemistry / Immunoprecipitation / Life Sciences / Lymphocytes T / Lymphocytes, Tumor-Infiltrating / Membrane proteins / Metastases / Metastasis / Mice / Nuclear Proteins / Oncology, Experimental / Patients / PD-1 protein / PD-L1 / PD-L1 protein / Plasmids / Protein binding / Protein-Ligand Interactions / Proteins / Radiation therapy / Radioresistance / Radiotherapy / Receptors / Repressor Proteins / Software / SPOP / T cells / TMEM160 / Tumor cells / Tumor Escape / Tumorigenesis / Tumors / Ubiquitin / Ubiquitination / Yeast